当前位置:首页 - 行情中心 - 维康药业(300878) - 财务分析 - 利润表

维康药业

(300878)

  

流通市值:33.26亿  总市值:33.42亿
流通股本:1.44亿   总股本:1.45亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入114,569,884.8369,775,938.28351,198,567.67370,849,453.15
  营业收入114,569,884.8369,775,938.28351,198,567.67370,849,453.15
二、营业总成本173,950,785.4479,431,824.89510,989,718.79414,716,527.66
  营业成本89,624,143.0633,910,536.12217,105,289.06195,105,928.34
  税金及附加1,868,155.041,505,227.4111,711,547.799,052,229.65
  销售费用53,286,353.9430,418,191.53200,591,036.15163,238,779.57
  管理费用20,193,443.149,612,289.1561,138,368.8133,169,543.96
  研发费用5,995,845.172,671,04214,185,931.3912,180,680.93
  财务费用2,982,845.091,314,538.686,257,545.591,969,365.21
  其中:利息费用3,782,750.261,935,369.669,335,228.934,200,156.35
  其中:利息收入848,072.42487,268.133,147,465.842,314,974.21
三、其他经营收益
  加:投资收益--91,114,06892,107,925.62
  资产处置收益-493,861.61-168,841.23-467,667.6-251,107.37
  资产减值损失(新)-5,002,495.311,541,958.53-90,259,277.96-123,728.8
  信用减值损失(新)6,894,944.484,867,447.87-3,183,567.33-6,588,421.43
  其他收益3,492,485.371,988,656.218,844,435.526,783,853.17
四、营业利润-54,489,827.68-1,426,665.23-153,743,160.4948,061,446.68
  加:营业外收入255,442.25267,133.282,988,544.683,082,327.88
  减:营业外支出2,047,875.441,057,649.57,521,368.497,315,564.82
五、利润总额-56,282,260.87-2,217,181.45-158,275,984.343,828,209.74
  减:所得税费用8,028,798.567,489,145.72-13,397,609.01-2,376,861.32
六、净利润-64,311,059.43-9,706,327.17-144,878,375.2946,205,071.06
(一)按经营持续性分类
  持续经营净利润-64,311,059.43-9,706,327.17-144,878,375.2946,205,071.06
(二)按所有权归属分类
  归属于母公司股东的净利润-64,219,669.11-9,854,658.34-147,426,253.4344,097,475.42
  少数股东损益-91,390.32148,331.172,547,878.142,107,595.64
  扣除非经常损益后的净利润-64,826,322.34-10,544,817.79-238,936,373.43-47,405,316.5
七、每股收益
  (一)基本每股收益-0.44-0.07-1.030.31
  (二)稀释每股收益-0.44-0.07-1.030.31
九、综合收益总额-64,311,059.43-9,706,327.17-144,878,375.2946,205,071.06
  归属于母公司股东的综合收益总额-64,219,669.11-9,854,658.34-147,426,253.4344,097,475.42
  归属于少数股东的综合收益总额-91,390.32148,331.172,547,878.142,107,595.64
公告日期2025-08-282025-04-292025-04-292024-10-28
审计意见(境内)保留意见
TOP↑